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540Among patients with coronary
artery disease (CAD), secondary
prevention with a combination of
antiplatelets, beta-blockers (BB),
angiotensin-converting enzyme in-
hibitors (ACEI)/angiotensin re-
ceptor blockers (ARB), and statins
reduces cardiac mortality andmyo-
cardial infarction (MI) (1).
Accordingly, clinical guidelines
and performance measures call for
the prescription of these medica-
tions to all eligible patients (1, 2).
However, the translation of
these recommendations to clinical
practice is poorly understood (3–5).See page 547One important factor in
optimal secondary prevention
may be the outpatient cardiology
practice where CAD patients aretreated. Prevention efforts are a major focus of care in this
setting, and longitudinal therapeutic relationships are often
established between the cardiac clinician and patient.
Therefore, the opportunity and motivation to provide
optimal secondary prevention in outpatient cardiology
practices is strong. However, little is known about secondary
prevention medication prescription patterns among CAD
patients in the outpatient setting. Understanding these
patterns and any variations in care can help identify higher
performing practices, whose techniques for delivering
optimal care can be better understood and potentially
generalized to all practices.
To understand outpatient practice patterns, we analyzed
data from the National Cardiovascular Data Registry
(NCDR) PINNACLE (Practice Innovation and Clinical
Excellence) registry, the largest outpatient quality improve-
ment registry of patients treated in ambulatory cardiology
clinics in the United States. We characterized practice
patterns and variation in secondary prevention medication
prescription rates and assessed the impact of practice site on
optimal prescription of these medications after accounting
for patient factors.Methods
Data source. Our analysis used data from the NCDR
PINNACLE registry. PINNACLE is the ﬁrst national,
prospective, outpatient-based cardiac quality improvement
registry of patients seen in cardiology practices in the
United States (6,7). The American College of Cardiology
Foundation (ACCF) launched the registry in 2008.Participating practices collect patient data at the point of care
for each outpatient visit. Patient data include demographics,
comorbidities, symptoms, vital signs, medications, contra-
indications to medications, and laboratory values.
Data elements are collected either by PINNACLE using
paper-based case report forms or by exporting a practice’s
electronic health record (EHR) to comprehensively capture
the requisite data elements for PINNACLE program
participation (6). Data collection is standardized through
written deﬁnitions, uniform data entry and transmission
requirements, and data quality checks.
Study population and patient eligibility. For our study, we
assessed PINNACLE patient and practice data col-
lected during index clinic visits of CAD patients, between
July 2008 and December 2010. CAD was deﬁned by the
treating clinician and included a history of MI, percuta-
neous coronary intervention (PCI), or coronary artery bypass
grafting (CABG). We deﬁned patient eligibility for 3
secondary prevention medication classes: BB, ACEI/ARB,
and statins, in accordance with the 2011 ACCF/American
Heart Association Task Force on Performance Measures and
American Medical Association-Physician Consortium for
Performance Improvement (2). We elected not to measure
anti-platelet use because over-the-counter medications such
as aspirin are incompletely captured in the practice EHRs
and the PINNACLE registry. Eligibility included BB
therapy for those with either a previous MI or a left
ventricular ejection fraction (LVEF) <40%, ACEI/ARB
therapy for those with either diabetes mellitus (DM) or
LVEF <40%, and statin therapy in those with a low-density
lipoprotein concentration 100 mg/dl. Although this
criterion for statin use has been expanded to include
patients with all levels of low-density lipoprotein, we elected
to use the more restrictive deﬁnition to conform to the 2011
performance measures guidelines. In addition, we elected to
use the 2011 performance measure for BB use, although
recent guidelines indicate that its use is optional for those
patients who had a remote (>3 years), uncomplicated MI.
Patients with documented medical, patient, or system
reasons for not being prescribed any of the studied medi-
cation classes were excluded from analyses for that parti-
cular class and clinical encounter. If there were no
documented reasons for not prescribing a medication, the
patient was considered eligible to receive the medication.
We also excluded data from practices that had fewer than
10 eligible CAD patients, as sample sizes that small cannot
be sufﬁciently modeled in regression analyses. For each
medication class, we also excluded those practices with
treatment rates of 0%, as this likely represented inadequate
documentation of medication prescription rather than
actual failures of treatment.
Outcomes. We analyzed combined and individual pre-
scription rates of the 3 medication classes among eligible
patients at the patient and practice levels (2). Evidence of
prescription was collected from the practice case report form
or EHR. Combined prescription rates were calculated as the
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541percentage of fulﬁlled “quality opportunities,” using the
method deﬁned by the Joint Commission (8). These were
calculated by dividing the number of medications prescribed
by the number of medications for which the individual
patient was eligible. Thus, a patient eligible for 2 of the 3
medication classes who received both prescriptions would
have a combined rate of 100%, whereas a patient eligible for all
3 medication classes who received 2 prescriptions would have
a combined rate of 67%. The optimal combined prescription
was deﬁned as fulﬁlling 100% of prescription opportunities.
Our primary analyses were based on the ﬁrst encounter
with each patient, as this represents the ﬁrst opportunity the
clinician has to prescribe the optimal combination of medi-
cations. However, we recognize that many clinicians choose
to prescribe these medications sequentially and over time,
rather than in a single visit, in order to avoid side effects or
other complications of therapy. Therefore, we conducted
a sensitivity analysis of the outcome to account for prescrip-
tion of the medication class at any visit over the year fol-
lowing the index visit. Because the last date for an index clinic
visit included in our cohort was December 2010, all patients
had at least 1 year of elapsed time after their index visit. This
approach can cause some variation in the number of eligible
patients compared to the ﬁrst encounter analysis, because
patients can become eligible or ineligible for different thera-
pies at visits after their index visit (e.g., new diagnosis of DM
or development of statin-induced myopathy).
Covariates. Patient factors that could affect prescription
patterns were identiﬁed based on prior studies and clinical
reasoning (5,6,9). These factors included demographics (age,
sex, insurance payer), clinical characteristics (dyslipidemia,
hypertension [HTN], DM, current smoker, peripheral
arterial disease [PAD], atrial ﬁbrillation or ﬂutter, history of
stroke or transient ischemic attack [TIA], MI within the
prior year, angina, CABG within the prior year, PCI within
the prior year), and heart failure. These variables were
collected for description and inclusion in our regression
models as covariates.
Statistical analysis. After specifying our study cohort, we
grouped patients by receipt of optimal combined medication
prescription and compared their characteristics using t-tests
for continuous variables and chi-square tests for categorical
variables. Next, median practice rates of optimal combined
and individual medication prescriptions were determined for
each practice and examined with descriptive plots. Practice
characteristics, stratiﬁed by practice prescription rates above
and below the median combined rate of medication
prescription, were compared using t-tests for continuous
variables and chi-square tests for categorical variables.
To control for differential distribution of patient factors
among practices, multivariable regression models for optimal
combined and individual prescription rates were constructed.
Practice was modeled as a random rather than ﬁxed effect.
Hierarchical modeling techniques were used to account for
clustering patients by practice. Variation in prescription rates
by practice site was calculated using a median rate ratio(MRR). The MRR estimates the differences between
prescription patterns for identical patients between 2
randomly selected practices. It can be interpreted as the
likelihood ratio that the same patient would receive
a different combination of prescriptions at 2 different
practices in our cohort (10,11). An MRR of 1.0 indicated
that no variation existed between practices. Thus, the MRR
is always 1. For example, an MRR of 1.5 indicates a 50%
likelihood that a similar patient would receive different
prescriptions at 2 different practices. It provides an estimate
of the effect size of the practice on the outcome, much as the
odds ratio estimates the effect size of patient factors on the
outcome (11,12). Based on prior literature, an MRR >1.2
indicates clinically signiﬁcant variation (13).
Signiﬁcant (>5%) missing data rates in our cohort
included 18.5% for smoking status, 5.7% for CABG within
the prior year, 5.7% for PCI within the prior year, 5.6% for
MI within the prior year, and 5.4% for insurance status. In
order to avoid case-wise deletion of those cases with missing
data points, we modeled a separate “unknown” category for
each of these data elements and included those categories in
our analysis.
Secondary analyses. We conducted several secondary
analyses to further explore our primary ﬁndings. First, we
hypothesized that practices with greater proportions of CAD
patients would have higher optimal prescription rates,
potentially due to improved familiarity and expertise in CAD
treatment. Therefore, we entered the practice proportion of
CAD patients in our regression models. Second, we
hypothesized that participation in the PINNACLE registry
would also lead to higher prescription rates because the
registry is a quality improvement initiative that provides
quarterly performance reports to participating practices.
Accordingly, we analyzed the subset of practices that
submitted data to PINNACLE using EHRs (n ¼ 29)
because these practices had both pre-PINNACLE and post-
PINNACLE participation data for analysis. We compared
prescription rates among these practices before and after
PINNACLE participation, as deﬁned by the date when the
practice entered into its contract with PINNACLE. Third,
we hypothesized that practices with longer participation in
PINNACLE, and thus more information about their
prescription rate performance and opportunities to improve
it, would have higher prescription rates. Thus, we included
PINNACLE participation in our models, measured as days
from the date of the contractual agreement between the
practice and PINNACLE . Fourth, we recognized that better
prescription rates among practices might actually represent
better documentation, rather than truly better performance.
Therefore, in line with prior studies, we measured the
correlation between practice performance rates and docu-
mentation of contraindications to medications (13). If better
performance were due to better documentation, then we
would expect higher correlation between performance rates
and documented medication exclusions. Conversely, the
absence of any correlation would suggest that better
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542performance is unlikely to be attributable to better docu-
mentation. Fifth, we hypothesized that larger practices
might have different rates of prescription performance than
smaller practices. Thus, we conducted a correlation analysis
between practice size and prescription performance. We also
included practice size as a covariate in our primary regres-
sion model.
All analyses were performed using SAS version 9.1 soft-
ware (SAS Institute, Cary, North Carolina).Results
Combined prescription rates. Between 2008 and 2010,
the PINNACLE registry contained data for 576,787
patients seen in 65 practices. After exclusion of patients
without CAD (Fig. 1) and practices with <10 eligible CAD
patients, our ﬁnal study cohort of patients eligible for all 3
medication types was 156,145 treated in 58 practices.
Among this cohort, 103,830 (66.5%) patients had their
optimal combination of medications prescribed at their index
clinic visit. This percentage increased to 69.7% (121,662 of
174,586 patients) after accounting for all visits among
eligible patients occurring within the year following the index
visit. These patients, compared to those who were not
prescribed their optimal combination of medications, were
older, more likely male, and more likely insured (Table 1).
They had higher rates of dyslipidemia, HTN, PAD, and
prior MI but lower rates of DM, stroke, and PCI.
Among the 58 practices in our cohort, the median prac-
tice prescription rate of the optimal combination of medi-
cations was 73.5%. Rates varied from 28.8% to 100%
(Fig. 2). After including all visits among eligible patients in
the year following the index visit, the median prescription
rate increased to 75.1% and ranged from 46.1% to 100%.Figure 1 Study Cohort Creation
Study cohort creation, identifying PINNACLE patients with CAD and eligibility for secondary
inhibitor; ARB ¼ angiotensin receptor blocker; BB ¼ beta-blocker; CAD ¼ coronary arteryBetween practices above and below the median prescription
rate, number and type of providers in a practice, length of
practice’s PINNACLE participation, and geographical
location of the practice were similar (Table 2).
After adjustment for patient factors, signiﬁcant practice
variations in optimal prescribing patterns of combined
medications were present (MRR 1.25 [95% conﬁdence
interval [CI]: 1.20 to 1.32]). After adjustment, patient
factors signiﬁcantly associated with higher rates of optimal
prescription were male sex, dyslipidemia, HTN, PAD, PCI
performed within the prior year, and heart failure (Table 3).
Patient factors signiﬁcantly associated with lower prescrip-
tion rates were prior stroke/TIA, MI occurrence within the
prior year, and DM.
Individual medication prescription rates. Among patients
eligible for individual medication classes, BBs were pre-
scribed in 73.3% (63,800 of 86,999) cases, ACEI/ARBs in
69.4% (55,933 of 80,552) cases, and statins in 68.2%
(18,833 of 27,628) cases. After inclusion of all visits among
eligible patients occurring within the year following the
index visit, these rates increased to 77.3%, 72.3%, and
72.5%, respectively. Unadjusted patient factors associated
with prescription are listed in Online Tables 1 to 3.
Among practices, the median prescription rate for BBs
was 78.4% (range: 35.2% to 100%), 75.5% (range: 39.1% to
100%) for ACEI/ARBs, and 73.3% (range: 10.7% to 100%)
for statins (Online Figs. 1 to 3). After inclusion of all visits
among eligible patients occurring within the year following
the index visit, these values increased to 79.4% (range:
46.2% to 100%) for BBs, 78.1% (range: 45.4% to 100%) for
ACEI/ARBs, and 77.7% (range: 41.8% to 100%) for statins.
After adjustment, practice was signiﬁcantly associated
with prescription of all medication classes. Adjusted MRR
values were 1.22 (95% CI: 1.18 to 1.28) for BBs, 1.19 (95%prevention medication prescription, is shown. ACEI ¼ angiotensin-converting enzyme
disease.
Table 1
Patient Characteristics by Optimal Combined Prescriptions of
Secondary Prevention Medications
Characteristic
Optimal Combination of Antiplatelet, BB, ACEI/ARB, and Statin
(N ¼ 156,145)
p ValueYes (n ¼ 103,830; 66.5%) No (n ¼ 52,315; 33.5%)
Age 68.0  11.9 67.4  13.4 <0.001
Male 65,797 (63.5%) 29,347 (56.2%) <0.001
Race <0.001
White 41,095 (39.6%) 19,161 (36.6%)
Black 4,694 (4.5%) 2,330 (4.5%)
Other 406 (0.4%) 204 (0.4%)
Missing 57,635 (55.5%) 30,620 (58.5%)
Insurance <0.001
None 3,810 (3.7%) 2,106 (4.0%)
Private 54,056 (52.1%) 30,401 (58.1%)
Public 38,751 (37.3%) 16,782 (32.1%)
Unknown 7,213 (6.9%) 3,026 (5.8%)
Current tobacco use <0.001
Yes 15,016 (14.5%) 7,449 (14.2%)
No 74,344 (71.6%) 36,225 (69.2%)
Unknown 14,470 (13.9%) 8,641 (16.5%)
Heart failure 39,387 (37.9%) 17,747 (33.9%) <0.001
Dyslipidemia 84,539 (81.4%) 38,283 (73.2%) <0.001
Diabetes 45,978 (44.3%) 25,702 (49.1%) <0.001
Hypertension 85,954 (82.8%) 39,886 (76.3%) <0.001
PAD 20,007 (19.3%) 8,811 (16.8%) <0.001
Prior stroke/TIA 15,000 (14.4%) 7,641 (14.6%) 0.397
Angina 14,747 (14.2%) 5,932 (11.4%) <0.001
Atrial ﬁbrillation 18,184 (17.5%) 9,359 (17.9%) 0.065
PCI within 12 months <0.001
Yes 22,489 (21.7%) 9,246 (17.7%)
No 75,137 (72.4%) 39,475 (75.5%)
Unknown 6,204 (6.0%) 3,594 (6.9%)
CABG within 12 months <0.001
Yes 14,213 (13.7%) 9,579 (18.3%)
No 83,360 (80.3%) 39,128 (74.8%)
Unknown 6,257 (6.0%) 3,608 (6.9%)
MI within 12 months <0.001
Yes 24,986 (24.1%) 14,351 (27.4%)
No 73,117 (70.4%) 34,462 (65.9%)
Unknown 5,727 (5.5%) 3,502 (6.7%)
Values are mean  SD or n (%).
ACEI ¼ angiotensin converting enzyme inhibitors; ARB ¼ angiotensin receptor blockers; BB ¼ beta-blocker; CABG ¼ coronary artery bypass graft;
MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; PCI ¼ percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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543CI: 1.16 to 1.26) for ACEI/ARBs, and 1.31 (95% CI: 1.24
to 1.44) for statins (Online Table 4). Adjusted patient
characteristics associated with individual medications are
also listed in Online Table 4.
Secondary analyses. We conducted 5 secondary analyses.
First, we assessed the impact of the proportion of patients
with CAD within a practice on practice prescription
patterns. The median proportion of patients with CAD
among practices was 58.8%. After adjustment, practices
with a greater proportion of CAD patients did not have
signiﬁcantly better prescribing patterns than practices with
a lower proportion of CAD patients. Second, we compared
optimal combined prescription rates before PINNACLE
participation to rates after participation among the 29PINNACLE practices with data available before and after
participation in PINNACLE. After adjustment, practices
were 14% less likely to prescribe the optimal combination
of medications in eligible patients prior to compared to
after PINNACLE participation (hazard ratio [HR]: 0.86,
95% CI: 0.75 to 0.98). Thus, PINNACLE participation
among this subset of practices appears to signiﬁcantly
contribute to documented practice prescription patterns of
optimal medications. Third, we assessed the impact of
length of participation in PINNACLE on prescription
patterns. The median length of PINNACLE participation
was 13.5 months. After adjustment, length of participa-
tion was not associated with an increased likelihood of
aggregate medication prescription. Fourth, we compared
Figure 2
Optimal Combined Prescriptions of Secondary
Prevention Medications by Practice
Among the 58 practices in our study cohort, rates of optimal combined prescrip-
tion of secondary prevention medications ranged from 28.8% to 100%. The
median rate of prescription was 73.5%.
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544correlations between documentation rates of medication
contraindications and prescription rates. The correlation
for BBs was 0.35 (p ¼ 0.01), 0.09 for ACEI/ARBs
(p ¼ 0.50), and 0.20 for statins (p ¼ 0.18). The only
signiﬁcant correlation occurred among BBs, suggesting
that better documentation may partially explain some BB
prescription patterns. However, among the other 2 medi-
cation classes, better documentation does not appear to
play a meaningful role in prescription performance. Fifth,
we assessed the impact of practice size on prescription
patterns. The correlation between the 2 variables
was 0.04 (p ¼ 0.79), indicating no signiﬁcant relation-
ship. After adjustment, practice size was not associated
with an increased likelihood of combined medication
prescription (odds ratio [OR]: 0.99, 95% CI: 0.99 to 1.00).
Discussion
Among U.S. cardiology practices participating in the
NCDR PINNACLE registry, we found that more thanone-third of patients with CAD were not prescribed an
optimal combination of BB, ACEI/ARBs, and statins. In
addition, practice prescription patterns varied widely. After
adjustment for patient factors, there was 25% likelihood that
different practices had different prescription patterns for
similar patients. Collectively, our ﬁndings suggest that
prescription of evidence-based CAD therapies is neither
optimal nor uniform and offers insights into opportunities to
further improve care among outpatients with CAD.
Prior studies of secondary prevention prescribing practices
in the ambulatory setting have illustrated substantial but
improving gaps in care. Substantial improvements have been
made in prescription of these medications at the point of
hospital discharge, but similar gains in the ambulatory
setting, where most CAD prevention efforts occur, were
slower to follow (14,15). In a 2001 survey of outpatient
medical practices, Stafford et al. (5) found that rates of
aspirin and BB use among CAD patients were well below
50%. Several years later, the international REACH
(Reduction of Atherothrombosis for Continued Health)
registry collected data for ambulatory care patterns among
patients with or at risk for cardiovascular disease (3,9,16).
Among U.S. patients, 77% of patients were prescribed anti-
platelet therapy, 51.8% were prescribed BBs, 49.5% were
prescribed ACEIs, and 76.9% were prescribed statins (9).
Follow-up assessments 4 years later found no signiﬁcant
change in rates (16). Most recently, Chan et al. (6), using
2008 to 2009 data from the PINNACLE registry, found
higher rates of secondary prevention medication prescrip-
tion among CAD patients. In their analysis, 84.9% of
patients were receiving anti-platelets, 86.4% received BB,
72.4% received ACEI/ARB, and 84.3% received lipid-
lowering agents.
Our PINNACLE study demonstrated lower rates of
medication prescription than those noted by Chan et al. (6),
potentially because of the inclusion of a larger and more
heterogeneous patient and practice population. We also
focused on the combined prescription of all eligible medi-
cations to patients, rather than just individual classes, as
a more accurate reﬂection of optimal preventive care and
maximal risk reduction. Accordingly, there may be merit to
using a “quality opportunities” paradigm in both the treat-
ment and performance measurement of CAD patients.
We found substantial variation in prescription patterns
by practice site. Although overall rates of secondary pre-
vention prescription have improved with time, the role of
the outpatient practice setting on these rates has not previ-
ously been characterized. A prior study from a U.S. cohort in
the REACH registry found that practice characteristics,
such as specialty type or geographic location, could signiﬁ-
cantly affect prescription rates (3). The initial data from
PINNACLE also suggested heterogeneity in practice pat-
terns by demonstrating substantial variation in compliance
rates (from 13% to 97%) for various cardiac performance
measures (6). However, neither of these studies directly
measured or compared prescription pattern variation by
Table 2
Practice Characteristics by Median Rates of Optimal Combined Prescription of
Secondary Prevention Medications
Practice Characteristic Location
CAD Medications Fulﬁllment
Rate Above Median (n ¼ 29)
CAD Medications Fulﬁllment
Rate Below Median (n ¼ 29) p Value
Number of MDs 2.0 (1.0–11.0) 11.0 (3.0–21.0) 0.170
Number of NPs 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.858
Number of providers 2.0 (1.0–14.0) 13.0 (3.0–27.0) 0.229
Months of PINNACLE
registry participation
21.0 (12.0–24.0) 12.0 (12.0–21.0) 0.067
Practice location Urban 24 (82.8%) 27 (93.1%) 0.170
Rural 5 (17.2%) 2 (6.9%)
Values are median (interquartile range) or n (%).
CAD ¼ coronary artery disease; IQR ¼ interquartile range; MD ¼ medical doctors; NP ¼ nurse practitioners.
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545practice site. Understanding this variation is an integral piece
of quality assessment, because effective quality improvement
efforts require understanding and targeting individual
practices.
Our analysis also directly explored the association of
outpatient practice in current prescribing patterns among
PINNACLE registry participants by using MRRs. OurTable 3
Practice and Patient Factors Associated With Optimal
Combined Prescriptions of Secondary Prevention
Medications Following Multivariable Adjustment
Factor
Optimal Combination of Antiplatelet
BB, ACEI/ARB, and Statin Drugs
Ratio (95% CI)
Practice median rate ratio 1.25 (1.20–1.32)*
Age 65 to 74 yrs 1.02 (1.00–1.04)
Age 75 yrs 0.99 (0.96–1.02)
Male 1.09 (1.06–1.11)*
Insurance
Private 1.01 (0.96–1.05)
Public 1.02 (0.99–1.06)
Unknown 1.04 (0.96–1.12)
Atrial ﬁbrillation 0.99 (0.96–1.02)
Dyslipidemia 1.15 (1.08–1.23)*
Hypertension 1.16 (1.10–1.21)*
Diabetes mellitus 0.89 (0.86–0.92)*
Current smoker
Yes 1.01 (0.99–1.02)
Unknown 0.96 (0.92–1.00)
PAD 1.07 (1.02–1.12)*
Prior stroke/TIA 0.96 (0.94–0.97)*
MI within 12 months
Yes 0.94 (0.90–0.97)*
Unknown 0.84 (0.68–1.03)
Angina 1.02 (0.99–1.06)
CABG within 12 months
Yes 0.90 (0.78–1.04)
Unknown 0.85 (0.76–0.94)*
PCI within 12 months
Yes 1.08 (1.05–1.11)*
Unknown 0.99 (0.91–1.08)
Heart failure 1.05 (1.02–1.08)*
*p <0.05
CI ¼ conﬁdence interval; other abbreviations as in Table 1.ﬁndings suggest that patients may receive suboptimal care
solely because of the practice where they choose to seek
care. These gaps are even more striking when one considers
that the voluntary participants in the PINNACLE registry
likely represent cardiology practices that are particularly
focused on providing high quality care. Although it is
encouraging that PINNACLE participation appeared to
increase the rates of optimal prescription, concerning
variation in practice still exists. Examining primary care
practices, where most CAD patients receive preventative
care, may demonstrate even larger variations in care. As
a result, our analysis both illustrates and likely underesti-
mates the true amount of variation in U.S. outpatient
practice.
The reasons behind this overall practice variation in
combined and individual medication prescription are
unclear. Incomplete documentation of medication contra-
indications or incorrect classiﬁcation of patient eligibility for
therapies may be a partial answer, although our secondary
analysis examining correlations between prescription rates
and contraindication notations suggests that the latter is not
a major contributor. Other sources of practice variation may
lie in differing clinician opinions about the efﬁcacy of
therapies, an unawareness of current recommendations,
competing interests during the clinical encounter, clinical
inertia, or practice patterns that can lead to omissions of
therapies (17,18). For example, cardiologists may rely on
a patient’s primary care provider to prescribe the appropriate
medications. Another fruitful area of inquiry may be
examination of prescribing patterns among multisite prac-
tices, as factors such as referral patterns within practices and
shared documentation protocols have also had an effect on
performance. Although our current cohort is too small to
explore these patterns, future analyses of PINNACLE as it
continues to grow would be instructive. Further investiga-
tion is warranted to understand these and other factors that
contribute to both high- and low-performing practices. As
with other clinical care processes that rely on systems and
some degree of standardization (such as rapid door-to-
balloon times in acute MI), the study of high-performing
practices may suggest needed improvements for low-
performing practices (19).
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546Study limitations. Our ﬁndings should be interpreted in
light of several considerations. First, as discussed above,
some of our ﬁndings may be due to incomplete docu-
mentation of medication contraindications or incorrect
classiﬁcation of medication eligibility, although our
secondary analyses suggest this is not a signiﬁcant concern.
In addition, as noted in Methods, there may be reasonable
and appropriate heterogeneity of practice around individual
medication use, such as the optional use of BBs in patients
with a remote history of an MI. Second, our ﬁndings are
derived from a registry of cardiology practices, which may
not represent the broader medical practice of cardiac
prevention. However, as mentioned earlier, we would
expect actual rates in broader practice to be, if anything,
worse. Third, we had limited data for practice character-
istics and thus were unable to provide extensive informa-
tion on both high- and low-performing practices. Finally,
we did not explore the lifestyle factors (e.g., smoking
cessation, weight loss) or the use of cardiac rehabilitation
therapy, which are also part of the CAD guidelines and
performance measures.
Conclusions
We found that more than one-third of CAD patients seen
in cardiology practices participating in the PINNACLE
registry were not prescribed their optimal combination of
prevention medications. In addition, we found signiﬁcant
variation in prescription patterns by practice, resulting in
substantial differences in how similar patients were treated at
different practices. Further investigation into reasons behind
these practice-level differences is needed to provide the right
care to the right patient, regardless of where they seek that
care.
Acknowledgment
The authors thank Katherine Fagan for editorial support.
Reprint requests and correspondence: Dr. Thomas M. Maddox,
Cardiology, 111B, VA Eastern Colorado Health Care System,
1055 Clermont Street, Denver, Colorado 80220. E-mail: thomas.
maddox@va.gov.
REFERENCES
1. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary
prevention and risk reduction therapy for patients with coronary and
other atherosclerotic vascular disease: 2011 update: a guideline from the
American Heart Association and American College of Cardiology
Foundation. J Am Coll Cardiol 2011;58:2432–46.
2. Drozda J Jr., Messer JV, Spertus J, et al. ACCF/AHA/AMA-PCPI
2011 performance measures for adults with coronary artery disease andhypertension: a report of the American College of Cardiology Founda-
tion/American Heart Association Task Force on Performance Measures
and the American Medical Association-Physician Consortium for
Performance Improvement. J Am Coll Cardiol 2011;58:316–36.
3. Kumar A, Fonarow GC, Eagle KA, et al. Regional and practice vari-
ation in adherence to guideline recommendations for secondary and
primary prevention among outpatients with atherothrombosis or risk
factors in the United States: a report from the REACH registry. Crit
Pathw Cardiol 2009;8:104–11.
4. McGlynn EA, Asch SM, Adams J, et al. The quality of health care
delivered to adults in the United States. N Engl J Med 2003;348:
2635–45.
5. Stafford RS, Radley DC. The underutilization of cardiac medications
of proven beneﬁt, 1990 to 2002. J Am Coll Cardiol 2003;41:56–61.
6. Chan PS, OetgenWJ, Buchanan D, et al. Cardiac performance measure
compliance in outpatients: the American College of Cardiology and
National Cardiovascular Data registry’s PINNACLE (Practice Inno-
vation and Clinical Excellence) program. J Am Coll Cardiol 2010;56:
8–14.
7. Chan PS, Oetgen WJ, Spertus JA. The Improving Continuous Cardiac
Care (IC(3)) program and outpatient quality improvement. Am J Med
2010;123:217–9.
8. Kahn CN III, Ault T, Isenstein H, Potetz L, Van Gelder S. Snapshot
of hospital quality reporting and pay-for-performance under Medicare.
Health Aff (Millwood) 2006;25:148–62.
9. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence,
recognition, and treatment of cardiovascular risk factors in outpatients
with atherothrombosis. JAMA 2006;295:180–9.
10. Larsen K, Petersen JH, Budtz-Jørgensen E, Endahl L. Interpreting
parameters in the logistic regression model with random effects.
Biometrics 2000;56:909–14.
11. Larsen K, Merlo J. Appropriate assessment of neighborhood effects on
individual health: integrating random and ﬁxed effects in multilevel
logistic regression. Am J Epidemiol 2005;161:81–8.
12. Goldstein HB, Browne W, Rasbash J. Partitioning variation in
multilevel models. Understanding Statistics 2002;1:223–31.
13. Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level
variation in warfarin use among outpatients with atrial ﬁbrillation (from
the NCDR PINNACLE program). Am J Cardiol 2011;108:1136–40.
14. Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute
myocardial infarction according to the specialty of the admitting
physician. N Engl J Med 1996;335:1880–7.
15. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for
patients with acute myocardial infarction in the National Registry of
Myocardial Infarction from 1990 to 2006. AmHeart J 2008;156:1045–55.
16. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of
4-year cardiovascular event rates in stable outpatients at risk of or with
atherothrombosis. JAMA 2010;304:1350–7.
17. Parchman ML, Pugh JA, Romero RL, Bowers KW. Competing
demands or clinical inertia: the case of elevated glycosylated hemo-
globin. Ann Fam Med 2007;5:196–201.
18. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy
intensiﬁcation and medication nonadherence for blood pressure control
in patients with coronary disease. Arch Intern Med 2008;168:271–6.
19. Bradley EH, Curry LA, Webster TR, et al. Achieving rapid door-to-
balloon times: how top hospitals improve complex clinical systems.
Circulation 2006;113:1079–85.Key Words: CAD - outpatient practice - secondary prevention.
APPENDIX
For supplemental ﬁgures and tables, please see the online version of this
article.
